Get notified when KZIA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes a going concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operating.
Kazia Therapeutics files preliminary prospectus for ADS and warrant offering; terms not yet priced
Filed August 27, 2026 · ~2 min read
Key Changes
-
high
Kazia is offering ADSs (each representing 500 ordinary shares) and warrants, but the number of ADSs and public offering price are left blank in this preliminary filing.
The Offering verify on EDGAR → -
medium
The ADSs last traded at $14.60 on August 26, 2026, but the offering price has not been set.
The Offering verify on EDGAR → -
high
Net proceeds will fund clinical development of paxalisib across multiple cancer indications, including TNBC, HR+/HER2- breast cancer, and colorectal cancer, plus working capital.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WLTH 10-Q) is open in full — no account needed.
Partner
Trade KZIA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify